Wednesday, May 23, 2018 11:37:13 AM
At this point they have every intent to continue progression of the $TPIV pipeline but I don't believe it to be nearly as important as the Marker therapies. From what I understand the large healthcare funds and research analysts aren't very high on the peptide vaccines $TPIV is developing. While Tapimmune's vaccines have shown promise many others have failed which apparently hasn't given them the best reputation. To be given any consideration by these entities we need more data, which will come. The Marker cell replacement therapies on the other hand have garnered a lot of attention. This should be obvious by the recent stock activity post merger announcement, the fact that Ted Tentoff from Piper Jaffray has joined all the calls post merger announcement, and the fact that Nomura Securities has chosen to act as advisor to Tapimmune in regard to the merger. Piper Jaffray and Nomura typically would not be involved with companies of Tapimmunes diminutive stature, at the time of the merger announcement barely pushing $30 Million market cap. These are big names and I expect coverage from Piper Jaffray, w/ a research report, to be initiated after the merger. Short answer being that Marker's cell replacement therapy is way more valuable at this point in time than Tapimmune's vaccines.
As far as the $TPIV results I believe that Q1 2019 would be the earliest we see any new data. This would be for the TPIV200 data in ovarian cancer. There is a possibility we see some data later on this year but I wouldn't hold my breath. That being said, I believe it is highly possible that the data we are supposed to see in Q1 next year will be delayed to Q2. As of the last financial report there was ~$2 million on the balance sheet. I wouldn't be surprised if they had to slow enrollment until the latest round of financing. With the addition of ~$5 million earlier this month they now have the resources to ramp it back up again. Basically what I'm saying is there is still a chance we see some data late this year or early next year but don't be surprised if it isn't until Q2 2019.
As for near term milestones I think the biggest will be the closing of this merger and with that the funding to carry the company through 2020. We should see multiple data releases over the next two years that should propel the SP higher without much risk for dilution. Probably not the answer you wanted to hear but it's what I believe based on my assumptions of when we should see $TPIV vaccine data.
As for your last question not a lot of research can be done to answer this one so again, all IMO only. I don't believe Nomura Securities would not be involved with such a tiny company under ordinary circumstances as I mentioned above. That being said, I expect they are going to make damn sure everything goes according to plan. They have already been in discussion for the next round of funding which should be the last round for quite some time. I believe the PR said this will be finalized at close of the merger so I don't expect to have any details until then. I do know that each company, $TPIV & Marker, have been valued by a neutral third party, potentially Nomura in this case, as is standard practice in these types of mergers. As we get closer we should get more SEC filings which will detail this out showing us the valuation put on both companies. I would bet the farm that Marker was valued a lot higher than $TPIV. My guess at least double but probably more, IMO only of course. Luckily these numbers will be made available so we won't have to guess. We just have to wait.
Friends don't let friends place market orders
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM